293 related articles for article (PubMed ID: 32493065)
1. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch.
Ruiz-Medrano J; Rodríguez-Leor R; Almazán E; Lugo F; Casado-Lopez E; Arias L; Ruiz-Moreno JM
Eur J Ophthalmol; 2021 May; 31(3):1135-1145. PubMed ID: 32493065
[TBL] [Abstract][Full Text] [Related]
2. Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?
Hernández Martínez A; Pereira Delgado E; Silva Silva G; Castellanos Mateos L; Lorente Pascual J; Lainez Villa J; García Vicente P; Almeida-González CV
Eur J Ophthalmol; 2020 Sep; 30(5):1091-1098. PubMed ID: 31096782
[TBL] [Abstract][Full Text] [Related]
3. Short-term outcomes of intravitreal dexamethasone in relation to biomarkers in diabetic macular edema.
Narnaware SH; Bawankule PK; Raje D
Eur J Ophthalmol; 2021 May; 31(3):1185-1191. PubMed ID: 32429696
[TBL] [Abstract][Full Text] [Related]
4. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
5. Early-switch versus late-switch in patients with diabetic macular edema: a cost-effectiveness study.
Ruiz-Moreno JM; Ruiz-Medrano J
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):941-949. PubMed ID: 36370170
[TBL] [Abstract][Full Text] [Related]
6. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema.
Castro-Navarro V; Cervera-Taulet E; Navarro-Palop C; Monferrer-Adsuara C; Hernández-Bel L; Montero-Hernández J
BMC Ophthalmol; 2019 Jan; 19(1):15. PubMed ID: 30634940
[TBL] [Abstract][Full Text] [Related]
8. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
10. DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study.
Iglicki M; Busch C; Zur D; Okada M; Mariussi M; Chhablani JK; Cebeci Z; Fraser-Bell S; Chaikitmongkol V; Couturier A; Giancipoli E; Lupidi M; Rodríguez-Valdés PJ; Rehak M; Fung AT; Goldstein M; Loewenstein A
Retina; 2019 Jan; 39(1):44-51. PubMed ID: 29697589
[TBL] [Abstract][Full Text] [Related]
11. Analysis of anatomical biomarkers in subtypes of diabetic macular edema refractory to anti-vascular endothelial growth factor treated with dexamethasone implant.
Castro-Navarro V; Cervera-Taulet E; Navarro-Palop C; Hernández-Bel L; Monferrer-Adsuara C; Mata-Moret L; Montero-Hernández J
Eur J Ophthalmol; 2020 Jul; 30(4):764-769. PubMed ID: 30832509
[TBL] [Abstract][Full Text] [Related]
12. Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response.
Demir G; Ozkaya A; Yuksel E; Erdogan G; Tunc U; Celal Ocal M; Sakır Goker Y
Clin Drug Investig; 2020 Feb; 40(2):119-128. PubMed ID: 31768784
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
15. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Intravitreal Dexamethasone Treatment in Eyes with Pretreated Chronic Diabetic Macular Edema.
Zandi S; Lereuil T; Freiberg F; Pfau M; Pfister IB; Gerhardt C; Michels S; Kodjikian L; Garweg JG
J Ocul Pharmacol Ther; 2017 Oct; 33(8):620-628. PubMed ID: 28836880
[TBL] [Abstract][Full Text] [Related]
17. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA.
Zhioua I; Semoun O; Lalloum F; Souied EH
Retina; 2015 Jul; 35(7):1429-35. PubMed ID: 26102440
[TBL] [Abstract][Full Text] [Related]
18. [Early efficacy of dexamethasone implant (OZURDEX
Sarda V; Fajnkuchen F; Nghiem-Buffet S; Grenet T; Chaine G; Giocanti-Auregan A
J Fr Ophtalmol; 2017 May; 40(5):408-413. PubMed ID: 28336283
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
20. Influence of prior treatment protocol on intravitreal dexamethasone implant behavior in patients with diabetic macular edema in real-world practice.
Moreno-Martinez A; Blanco-Marchite C; Copete S
Expert Opin Drug Saf; 2024 Feb; 23(2):199-205. PubMed ID: 38234187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
